GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
- Conditions
- Small Bowel Crohn's Disease
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 78
- Registration Number
- NCT03046056
- Locations
- 🇺🇸
Gastro One, Germantown, Tennessee, United States
🇦🇹Medical University of Innsbruck, Department of Internal Medicine I, Innsbruck, Austria
🇺🇸University of Miami Crohn's and Colitis Center, Miami, Florida, United States
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 59
- Registration Number
- NCT03036852
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇳🇿Auckland City Hospital, Grafton, Auckland, New Zealand
🇬🇧Chelsea and Westminster Hospital, London, United Kingdom
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 95
- Registration Number
- NCT03036839
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸James J. Peters VA Hospital, Bronx, New York, United States
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 216
- Registration Number
- NCT03022981
- Locations
- 🇺🇸
Johns Hopkins University (JHU) - The Johns Hopkins Hospital (JHH), Baltimore, Maryland, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT02996682
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT02994056
- Locations
- 🇺🇸
Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States
🇺🇸Tampa General Medical Group, Tampa, Florida, United States
🇺🇸Digestive Disease Associates, PA, Catonsville, Maryland, United States
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Conditions
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 490
- Registration Number
- NCT02979613
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany